Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
October 24, 2017

Emerging immune checkpoint targets now being explored in combination trials

GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development.

GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development. When looking at four solid tumors—bladder cancer, breast cancer, cervical cancer, and colorectal cancer (CRC)—the analysis of Phase I/II to Phase III trials reveals a large majority of emerging immune checkpoint targets being explored in combination.

In the figure above, the number of clinical trials exploring immune checkpoint targets for these four indications are presented. Breast cancer and CRC show the highest number of trials, with nine and 10 trials, respectively. In these two solid tumor types, combination trials accounted for more than 85% of clinical trials.

Based on an analysis of GlobalData’s database, the Pharma Intelligence Center, most combination trials include a programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor. GlobalData anticipates that emerging checkpoint modulators will increase the response rate of current PD-1/PD-L1 inhibitor therapies, with PD-1/PD-L1 inhibitors becoming backbone therapies for most immuno-oncology therapies.

Related Reports

GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, GDHC009PFR.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU